» Articles » PMID: 34864781

Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction: An 18-Year Analysis of Temporal Trends, Epidemiology, Management, and Outcomes

Overview
Journal Shock
Date 2021 Dec 5
PMID 34864781
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are limited data on the temporal trends, incidence, and outcomes of ST-segment-elevation myocardial infarction-cardiogenic shock (STEMI-CS).

Methods: Adult (>18 years) STEMI-CS admissions were identified using the National Inpatient Sample (2000-2017) and classified by tertiles of admission year (2000-2005, 2006-2011, 2012-2017). Outcomes of interest included temporal trends, acute organ failure, cardiac procedures, in-hospital mortality, hospitalization costs, and length of stay.

Results: In ∼4.3 million STEMI admissions, CS was noted in 368,820 (8.5%). STEMI-CS incidence increased from 5.8% in 2000 to 13.0% in 2017 (patient and hospital characteristics adjusted odds ratio [aOR] 2.45 [95% confidence interval {CI} 2.40-2.49]; P < 0.001). Multiorgan failure increased from 55.5% (2000-2005) to 74.3% (2012-2017). Between 2000 and 2017, coronary angiography and percutaneous coronary intervention use increased from 58.8% to 80.1% and 38.6% to 70.6%, whereas coronary artery bypass grafting decreased from 14.9% to 10.4% (all P < 0.001). Over the study period, the use of intra-aortic balloon pump (40.6%-37.6%) decreased, and both percutaneous left ventricular assist devices (0%-12.9%) and extra-corporeal membrane oxygenation (0%-2.8%) increased (all P < 0.001). In hospital mortality decreased from 49.6% in 2000 to 32.7% in 2017 (aOR 0.29 [95% CI 0.28-0.31]; P < 0.001). During the 18-year period, hospital lengths of stay decreased, hospitalization costs increased and use of durable left ventricular assist device /cardiac transplantation remained stable (P > 0.05).

Conclusions: In the United States, incidence of CS in STEMI has increased 2.5-fold between 2000 and 2017, while in-hospital mortality has decreased during the study period. Use of coronary angiography and PCI increased during the study period.

Citing Articles

The Price We Pay: Cardiogenic Shock After Acute Myocardial Infarction.

Vallabhajosyula S, Ahmad K JACC Adv. 2024; 3(8):101048.

PMID: 39372364 PMC: 11450903. DOI: 10.1016/j.jacadv.2024.101048.


The Price We Pay for Progression in Shock Care: Economic Burden, Accessibility, and Adoption of Shock-Teams and Mechanical Circulatory Support Devices.

Vallabhajosyula S, Sinha S, Kochar A, Pahuja M, Amico Jr F, Kapur N Curr Cardiol Rep. 2024; 26(10):1123-1134.

PMID: 39325244 DOI: 10.1007/s11886-024-02108-4.


Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices.

Senman B, Jentzer J, Barnett C, Bartos J, Berg D, Chih S J Am Heart Assoc. 2024; 13(6):e031979.

PMID: 38456417 PMC: 11009990. DOI: 10.1161/JAHA.123.031979.


Effect of Cardiovascular Risk Factors on 30-Day All-Cause Mortality in Cardiogenic Shock.

Forner J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Behnes M J Clin Med. 2023; 12(14).

PMID: 37510985 PMC: 10381971. DOI: 10.3390/jcm12144870.


Organ dysfunction, injury, and failure in cardiogenic shock.

Shirakabe A, Matsushita M, Shibata Y, Shighihara S, Nishigoori S, Sawatani T J Intensive Care. 2023; 11(1):26.

PMID: 37386552 PMC: 10308671. DOI: 10.1186/s40560-023-00676-1.